Description
⋅ reasons for the downmove:
US Food and Drug Administration (FDA)
had raised concerns over the Troponin device’s temperature range
close facility in Sweden and move it to Ireland, which
will reduce its cost base to US1.5mln from US9mln
accounts will include a US50mln write-off.
cutting 40 jobs.
Trinity will engage with the FDA for the approval
being investigated for possible violations of federal securities law
reasons for an upmove:
sells products in over 110 countries
FDA finally approves !